Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,915 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1791
- Phase 1/Phase 2478
- Phase 3344
- Phase 4125
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia280
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts102
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,915 total
- NCT07350863RecruitingPhase 1
U69-CART cells for relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma
This trial tests a new type of cell therapy (U69-CART cells) that targets a specific protein (CCR9) found on leukemia cells in people whose T-cell acute lymphoblastic leukemia or lymphoma has come back or hasn't responded to standard treatments. The goal is to see if this therapy can help control the disease.
Suzhou, JiangsuAges 15–75 - NCT07349849RecruitingEarly Phase 1
mRNA Drug Targeting CD19 for Blood Cancers
This study tests a new mRNA-based medicine that targets CD19 on cancer cells. It is for people with B-cell lymphoma or leukemia who have run out of standard treatment options.
Chongqing, Chongqing MunicipalityAges 18–70 - NCT07344818RecruitingEarly Phase 1
CAR-T cell therapy targeting CD19 and CD20 for hard-to-treat B-cell lymphoma
This early-stage study tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and CD20, on your lymphoma cells. It is for people with aggressive B-cell lymphoma that has returned or not responded after several treatments. The goal is to see if this therapy can help shrink the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07349498Recruiting
Heart health after stem cell transplant
This study follows patients who have had a stem cell transplant to see how their heart and blood vessels are doing over time. It helps doctors learn about long-term heart risks after transplant.
Beijing, Beijing MunicipalityAges Any age - NCT07347171RecruitingPhase 1
Testing CG009301 for blood cancers that returned or didn't respond
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
NanchangAges 18–75 - NCT06864000Recruiting
Genetic study of a brain condition called CAA
This study looks at the genetic causes of cerebral amyloid angiopathy (CAA), a condition where proteins build up in small brain blood vessels. It aims to better understand the disease and may help guide future treatments.
RouenAges 18–99 - NCT06281483Recruiting
PRP vs PRF vs standard care for chronic skin ulcers
This study tests whether a treatment made from your own blood (platelet-rich plasma or platelet-rich fibrin) can help heal chronic skin ulcers better than standard care. If you have a non-healing ulcer that fits the size and duration criteria, and you are generally healthy, you may be able to participate.
CairoAges 18–65 - NCT07341191RecruitingPhase 2
Sonrotoclax and zanubrutinib before CAR-T for mantle cell lymphoma
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) given before your planned CAR-T cell therapy. The goal is to see if this approach can help control the lymphoma while you wait for CAR-T.
Calgary, AlbertaAges 18 years+ - NCT07336472RecruitingPhase 1/Phase 2
IBI3003 for relapsed or refractory multiple myeloma
This trial tests a new drug called IBI3003 for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if IBI3003 is safe and effective.
Scottsdale, ArizonaAges 18 years+ - NCT07336823RecruitingEarly Phase 1
JY232 CAR-T cell therapy for relapsed multiple myeloma
This trial tests an investigational CAR-T cell therapy called JY232 for people with multiple myeloma that has returned or not responded to at least two prior treatments. The therapy targets a protein called BCMA on myeloma cells to help your immune system fight the cancer.
Foshan, GuangdongAges 18–75 - NCT07342478RecruitingPhase 3
Comparing two BTK inhibitors for CLL/SLL after prior treatment
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
Skokie, IllinoisAges 18 years+ - NCT07338604RecruitingEarly Phase 1
UTAA07 cell therapy for relapsed CD7+ blood cancers
This trial tests a new cell therapy called UTAA07 for people with blood or lymph cancers that have returned or not responded to other treatments. It is designed for cancers that carry a specific marker called CD7, and aims to see if this therapy can help control the disease.
Suzhou, JiangsuAges 18 years+ - NCT07342179Recruiting
Monitoring immune cells after CAR-T therapy for myeloma
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
PoitiersAges 18 years+ - NCT07341698Recruiting
Prehabilitation before stem cell transplant for blood cancer
This trial tests a prehabilitation program for patients with blood cancer who are scheduled for an allogeneic stem cell transplant. The goal is to help improve your physical and emotional strength before the transplant.
Copenhagen, DenmarkAges 18 years+ - NCT07341867RecruitingPhase 1
Dose changes for cancer treatment in people with Duffy null
This trial tests if changing the dose of certain chemotherapy drugs can help people with a genetic trait called Duffy null avoid side effects like low white blood cell counts. It is for people with multiple myeloma or triple-negative breast cancer starting specific treatments.
Boston, MassachusettsAges 18 years+ - NCT07338344RecruitingPhase 2
Luspatercept with thalidomide for beta-thalassemia patients
This study tests whether a combination of two drugs, luspatercept and thalidomide, can help people with beta-thalassemia who need regular blood transfusions. It aims to reduce the number of transfusions needed.
Shenzhen, GuangdongAges 18–75 - NCT07339345RecruitingPhase 2/Phase 3
Testing a combination therapy for hemophagocytic lymphohistiocytosis
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
Beijing, Beijing MunicipalityAges 14–70 - NCT06060782RecruitingPhase 1
Chemo combo for high-risk blood cancer transplant patients
This trial tests a combination of drugs (thiotepa, cyclophosphamide, clarithromycin, and cytarabine) before a stem cell transplant. It is for people with certain types of blood cancer who have responded well to earlier treatment.
Zhuhai, GuangdongAges 18–65 - NCT02781883RecruitingPhase 2
Test drug BP1001 with venetoclax and decitabine for AML
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT06605586RecruitingPhase 1/Phase 2
Test of tasquinimod for myelofibrosis that stopped responding to JAK inhibitor therapy
This trial tests an oral drug called tasquinimod for people with myelofibrosis that no longer responds to or cannot take a JAK inhibitor. The goal is to see if tasquinimod can help shrink an enlarged spleen and improve symptoms.
AachenAges 18 years+ - NCT07332507RecruitingPhase 1
Testing teclistamab for recurrent plasmablastic lymphoma
This trial tests a new drug called teclistamab for people with plasmablastic lymphoma that has come back or not responded to standard treatments. The goal is to see if teclistamab can shrink tumors and control the disease.
Duarte, CaliforniaAges 18 years+ - NCT07328503RecruitingPhase 2
CD22 CAR T-cells to prevent relapse after CD19 CAR T-cell therapy
This trial tests if giving a second type of CAR T-cell therapy that targets CD22 can help keep B-cell acute lymphoblastic leukemia (ALL) in remission for people who are already in remission after CD19 CAR T-cell treatment. It aims to reduce the risk of the cancer coming back.
Bethesda, MarylandAges 3–65 - NCT06864975RecruitingPhase 4
Different doses of ADVATE for immune tolerance in boys with hemophilia A and inhibitors
This trial tests how different doses and schedules of the factor VIII medicine ADVATE can train the immune system to accept factor VIII again in boys with hemophilia A who have developed inhibitors. The goal is to find a better way to help their bodies stop blocking the treatment.
Beijing, Beijing MunicipalityAges birth–18 years - NCT07325006Recruiting
How Doctors' Behavior Affects Cancer Distress
This study looks at how doctors' behavior affects the distress cancer patients feel. It's for patients who are getting or recently finished radiation at Mayo Clinic in Rochester.
Rochester, MinnesotaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,915 recruiting hematology studies from the U.S. registry right now, out of 7,288 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.